Member Info for crumbs

Yes.. on that though we can expect the teams all know a few weeks ahead of the announcement...Of course yesterdays RNS if not GC related very much means things with BioNtech are getting serious

BTW well done to that team... £19 million not to be sniffed at

Dunno... maybe inananco was right about timing to fit in with closed markets... this winner not involving any listed companies and obviously already already involved CRUK... though till we know we do not know :)

Found one of this years winners already
this team
https://www.cancerresearchuk.org/funding-for-researchers/how-we-deliver-research/grand-challenge-award/Understanding-why-cancers-grow-in-some-tissues-and-not-in-others

https://planetradio.co.uk/hits-radio/manchester/news/manchester-scientists-to-receive-largest-ever-grant-for-cancer-study/

Yeah, that is the term used but you have to be looking in the right place and know what you are seeing... LD makes it sound so simple :)

'The company is “extremely cautious when it comes to any kind of megamerger,” Roche Chairman Christoph Franz told CNBC at the World Economic Forum in Davos, Switzerland. Not only are huge deals costly, money-wise, but integrating big buyouts costs time and effort that's "deviating you, maybe from some of your core activities, like, for example, research and development,” Franz told the network.

“That’s the reason why we are focusing on targeted ideas, outside our company, and then creating partnerships," Franz said, adding that in some cases Roche would do some small- or medium-sized deals.'

https://www.fiercepharma.com/pharma/roche-chairman-plans-to-avoid-megadeals-but-don-t-discount-smaller-m-a-cnbc

Your winning again:) 152,500

Another way of describing it could be ...L Durrant is the top Onco Immunologist in the World today...
Now seeing as the Cancer treatment market is going to be Immunotherapy based if that number one Immunologist had a company you could invest in ... well, the rest is easy... the show is just beginning but who has a ticket!

Scattergun approach as you once said :)
I dunno.. maybe they could do a deal on the modi1 vaccine whilst BioNtech does the TCR deal... all kinds of possibilities but yeah they seem desperately trying to get something... they did a big deal with Immunocore recently too ...

Possibility they will have it on their twitter feed.. seems to have been very GC active...
https://twitter.com/CRUKresearch

Also.. you may find a neo antigen ...and have great success in many of a patients tumours but one just may have differing neo antigens... meaning failure to cure...

The mindsets of pharma I guess... you can see how attached Merck is to the idea Keytruda is the entire future and bolshy with the whole it is going to be Keytruda plus x in combo now all go and fight it out to be x... yet in 5 years time CI might be looking like ending up the niche product x to mix in combo with other therapies that are themselves better... the science is not sitting still..but I guess when your currently raking in the $billions of your approved CI it can kinda make you feel invincible

Why... this from yesterdays RNS should get you curious.. but definitely not hysterical :)

'spearheading the new TCR therapeutics'

TCR.... how hot an area?

The TCR deal-making spree intensifies as Roche commits up to $2B in Adaptive Biotech to develop personalized cancer drugs

https://endpts.com/tcr-deal-spree-intensifies-as-roche-commits-up-to-2b-in-adaptive-biotech-to-develop-personalized-cancer-drugs/

“Cellular therapy approaches in cancer have been limited by the inability to effectively screen and translate the immune response to patient-specific neoantigens. Accurate recognition of such neoantigens is a major driver in the activity of novel immunotherapies,” said Adaptive co-founder Harlan Robins in a statement.https://endpts.com/tcr-deal-spree-intensifies-as-roche-commits-up-to-2b-in-adaptive-biotech-to-develop-personalized-cancer-drugs/https://endpts.com/tcr-deal-spree-intensifies-as-roche-commits-up-to-2b-in-adaptive-biotech-to-develop-personalized-cancer-drugs/

There were a spate of TCR deals and announcements in 2018: TCR2 Therapeutics is planning a $100 million-plus IPO, Gilead-owned CAR-T player Kite Pharma has paid $10 million to access HiFiBiO’s TCR tech platform, bluebird bio tied up with neoantigen biotech Gritstone to look for new targets to beef up its TCR pipeline, and joined forces with Regeneron to develop TCR targets in a five-year alliance.

There was a deal lined up... we don't know who with but they pulled the rug... a lot to do with GSK having such a big cancer vaccine failure... to do a big deal on a cancer vaccine after that would have put pharma x's BOD on the spot... even though they would have been buying into a vaccine that actually works!.... anyways onwards... and the thing is... what is Mellman Genentech/Roche doing on PBP?? ok I get from a scientific perspective why but commercial wise?... BioNtech we know .. but seeing as Genentech just began there own TCR program to rival BioNtech... makes you think...

Yeah... What made Immunocore a biotech unicorn worth £1 billion... well it was not it's tech lets face it immtacs compared to SCIB1 in trial did not impress though they are trying to find some 'niche' commercial space... much like Amgen and their V tec... yet Immunocore is a £1billion unicorn :).... pi are being given a great chance here...

Yes throw in non-toxicity and possibly being able to create a regime to 'cure' a majority of patients and the figures become unbelievable when you realise treatments would cover pretty much all cancer indications and insurance companies are willing to accept the huge bill of cell therapies... so long as they 'work' ... in the long run no matter the cost of it a cure becomes cost-effective... And there is a whole world of potential patients

It is just great that Doc Klausner is really excited about the science of this year's finalists he says :
'how really superb scientists were changing the way they were thinking because of the grand challenge which is something we walked away with perhaps more this time than last time'

Yes, Mellman and Sahin got to see things Lindy's way lol.....

£20 million prize that could possibly fund new staff and stuffs... and fund new trials... not that any of that is happening here

I know... which is why I avoided mentioning PBP might even win a prize

For some more GC build up... this should help

“The thing that really excited ... us about the science is … how really superb scientists were changing the way they were thinking because of the Grand Challenge” - Dr Rick Klausner, Chair of the #CRUKGrandChallenge Advisory Panel | meet the round 2 funded teams in 2 days

https://twitter.com/CRUKresearch/status/1087369294072213504

Bring it on!!